AtriCure (ATRC) Long-Term Investments (2011 - 2023)

AtriCure (ATRC) has reported Long-Term Investments for 11 consecutive years, with $7.6 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Long-Term Investments fell 88.18% year-over-year to $7.6 million; the TTM figure through Jun 2023 stood at $7.6 million (down 88.18% YoY), while the FY2022 annual figure was $51.5 million, down 50.63% from the prior year.
• Long-Term Investments declined to $7.6 million in Q2 2023 per ATRC's latest filing, from $25.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $105.1 million in Q3 2021 and bottomed at $7.6 million in Q2 2023.
• Historically, Long-Term Investments has averaged $40.7 million across 5 years, with a median of $23.0 million in 2019.
• Annual changes were most pronounced in 2022 — Long-Term Investments jumped 672.59% — and 2023, when it plunged 88.18%.
• AtriCure's Long-Term Investments stood at $12.7 million in 2019, then advanced by 11.86% to $14.2 million in 2020, then surged by 635.91% to $104.3 million in 2021, then plunged by 50.63% to $51.5 million in 2022, then sank by 85.25% to $7.6 million in 2023.
• Business Quant data shows ATRC's Long-Term Investments at $7.6 million in Q2 2023, $25.6 million in Q1 2023, and $51.5 million in Q4 2022.